Efficacy of Etoricoxib on Peripheral Hyperalgesia

Exclusion Criteria

• •Excluded will be patients Parkinson's disease or a history of cerebral vascular insult or nerve injury.
• •Excluded will be also all patients with contradictions for the use of Etoricoxib:
• •Hypersensitivity to the active substance or to any of the excipients.
• •Active peptic ulceration or active gastrointestinal (GI) bleeding.
• •Patients who have experienced bronchospasm, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria, or allergic-type reactions after taking acetyl-salicylic acid or NSAIDs including COX-2 (cyclooxygenase-2) inhibitors.
• •Pregnancy and lactation
• •Severe hepatic dysfunction (serum albumin \<25 g/l or Child-Pugh score ≥10).
• •Estimated renal creatinine clearance \<30 ml/min.
• •Inflammatory bowel disease.
• •Congestive heart failure (NYHA II-IV).
• •Patients with hypertension whose blood pressure is persistently elevated above 140/90mmHg and has not been adequately controlled
• •Established ischemic heart disease, peripheral arterial disease, and/or cerebrovascular disease.
• •Intake of one of the following drugs (current or in the last 3 days)
• •* selective-serotonin-reuptake-inhibitor
• •* cetoconazole
• •* rifampicin
• •* phenytoin
• •* carbamazepine
• •* dexamethasone or other systemic corticoids
• •* traditional nonsteroidal antiphlogistics
• •* cyclooxygenase-inhibitors
• •* immunosuppressives
• •* TNF-α-inhibitors